Evergreen Capital Management 13F: Cuts REGN Stake by $2.7M

Evergreen Capital Management lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 19.9% during the quarter, according to a Form 13F filing on October 23, 2026. The firm sold 3,547 shares of the biotechnology company, ending the period with 14,214 shares. The remaining position held an estimated market value of $10,778,102 at the time of the disclosure. Regeneron closed at $805.02 on the filing date.

REGN Regeneron Pharmaceuticals, Inc.

$819.09 ▲ +5.92% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Evergreen Capital Management's Regeneron Pharmaceuticals, Inc. Position

The fund pared back its exposure to Regeneron by nearly a fifth, cutting its holdings down from 17,661 shares to 14,214 shares. This reduction brought the total value of the investment down to roughly $10.8 million.

Other Institutional Activity in Regeneron Pharmaceuticals, Inc.

Other major investment managers also adjusted their positions in the biotech firm. SteelPeak Wealth sold out of its entire position, unloading 21,939 shares to end with zero holdings. Dodge & Cox reduced its holdings by 138,120 shares, or 3.0%, finishing with 4,458,238 shares valued at about $2.72 billion. On the buying side, Dodge & Cox Inc. grew its stake by 412,838 shares, or 9.3%, bringing its total to 4,871,137 shares worth roughly $3.92 billion. Franklin Resources, Inc. added 49,813 shares for a 1.8% increase, ending with 2,771,839 shares valued at $2.23 billion. Meanwhile, Nuveen, LLC trimmed its position by 45,017 shares, or 2.2%, to hold 2,019,974 shares worth approximately $1.63 billion.

Regeneron Pharmaceuticals, Inc. Stock Up 1.7%

Shares recently traded around $819.09 as of October 24, 2026, sitting 1.7% above their close on the filing date. The stock has traded between a 52-week low of $572.75 and a 52-week high of $859.34. It trades above both its 50-day moving average of $791.39 and its 200-day moving average of $736.05.

Recent Earnings

The company reported trailing twelve-month revenue of $15.53 billion alongside earnings of $40.44 per share. Profitability metrics show a net profit margin of 27.9% and a return on equity of 14.0%. The company's next financial results are slated for release on October 30, 2026.

Dividend

Regeneron pays an annual dividend rate of $3.76 per share, which translates to a dividend yield of 0.46%. The company distributes 9.0% of its earnings as dividends.

Insider Buying and Selling at Regeneron Pharmaceuticals, Inc.

Company insiders executed several transactions prior to the filing. Director Kathryn Ph.D. Guarini sold 400 shares on August 10, 2026, at an average price of $800.00 for a total value of $320,000. Guarini sold another 400 shares on September 2, 2026, at $850.00 per share, totaling $340,000. Officer Marion E. McCourt disposed of 2,346 shares on September 3, 2026, valued at approximately $2.0 million. Co-Chief Scientific Officer Andrew J. Murphy sold 4,147 shares under a pre-arranged Rule 10b5-1 plan on October 14, 2026, at an average price of $772.70, generating about $3.2 million.

Analysts Set New Price Targets

Analyst activity in October included several updates to ratings and price targets. On October 7, 2026, Truist Securities maintained its Buy rating while lifting its price target from $772.00 to $780.00. RBC Capital maintained a Sector Perform rating on October 8, 2026, raising its target from $737.00 to $810.00. UBS upgraded the stock to a Buy on October 15, 2026, significantly increasing its price target from $660.00 to $978.00. Piper Sandler maintained an Overweight rating on October 19, 2026, adjusting its target from $854.00 to $865.00. Finally, TD Cowen maintained a Buy rating on October 21, 2026, raising its target from $960.00 to $980.00. Across the broader analyst community, the stock carries a consensus Buy recommendation with 27 analyst opinions and a mean price target of $867.33.

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals discovers and develops specialty medicines focused on treating serious medical conditions. Its research targets eye diseases, allergic and inflammatory disorders, cardiovascular and metabolic problems, neurological and rare conditions, infectious diseases, and oncology. The Tarrytown, New York-based firm brings in multi-billion dollar annual sales through its commercialized drug portfolio.

Bottom Line

Investors will look to Regeneron's upcoming earnings report on October 30, 2026, for further insight into the drugmaker's revenue growth and pipeline progress. Institutional and insider transactions will continue to provide signals on how market participants view the stock following its recent run toward its 52-week highs.